State of New Jersey Common Pension Fund D trimmed its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) by 10.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,994 shares of the company’s stock after selling 5,214 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.09% of Prestige Consumer Healthcare worth $2,276,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of America Corp DE grew its stake in shares of Prestige Consumer Healthcare by 6.5% in the 4th quarter. Bank of America Corp DE now owns 358,699 shares of the company’s stock valued at $21,754,000 after purchasing an additional 21,826 shares during the period. Cubist Systematic Strategies LLC grew its stake in shares of Prestige Consumer Healthcare by 95.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 57,520 shares of the company’s stock valued at $3,489,000 after purchasing an additional 28,127 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at approximately $8,111,000. CWM LLC bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at approximately $1,930,000. Finally, Nordea Investment Management AB grew its position in Prestige Consumer Healthcare by 3.9% during the 1st quarter. Nordea Investment Management AB now owns 141,625 shares of the company’s stock worth $7,567,000 after acquiring an additional 5,287 shares during the last quarter.
Prestige Consumer Healthcare Stock Down 1.0 %
NYSE:PBH opened at $59.54 on Thursday. The stock’s fifty day moving average price is $57.55 and its two-hundred day moving average price is $56.62. Prestige Consumer Healthcare Inc. has a 52-week low of $51.70 and a 52-week high of $63.83. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.21 and a current ratio of 2.04. The company has a market cap of $2.97 billion, a price-to-earnings ratio of 14.74, a P/E/G ratio of 1.82 and a beta of 0.50.
Analysts Set New Price Targets
A number of equities research analysts recently commented on PBH shares. Oppenheimer upgraded Prestige Consumer Healthcare from a “market perform” rating to an “outperform” rating and set a $63.00 price target on the stock in a research report on Monday, May 9th. Jefferies Financial Group upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating and increased their price target for the stock from $65.00 to $70.00 in a research report on Tuesday, May 10th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $80.50.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
- Get a free copy of the StockNews.com research report on Prestige Consumer Healthcare (PBH)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.